Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, and Macau; and Nicox SA to generate various therapeutics for the treatment of certain ophthalmic conditions, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-621-7722
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$346.64 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/7/2019 (Estimated)
OptionableOptionable
Ironwood Pharmaceuticals (NASDAQ:IRWD) Frequently Asked Questions
What is Ironwood Pharmaceuticals' stock symbol?
Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."
How were Ironwood Pharmaceuticals' earnings last quarter?
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its quarterly earnings data on Wednesday, February, 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.17) by $0.15. The biotechnology company had revenue of $130.70 million for the quarter, compared to analyst estimates of $96.57 million. The company's revenue for the quarter was up 38.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.14) EPS. View Ironwood Pharmaceuticals' Earnings History.
When is Ironwood Pharmaceuticals' next earnings date?
What guidance has Ironwood Pharmaceuticals issued on next quarter's earnings?
Ironwood Pharmaceuticals updated its FY 2019 earnings guidance on Wednesday, February, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $370-390 million, compared to the consensus revenue estimate of $377.33 million.
What price target have analysts set for IRWD?
13 brokers have issued twelve-month price targets for Ironwood Pharmaceuticals' shares. Their forecasts range from $11.00 to $25.00. On average, they expect Ironwood Pharmaceuticals' stock price to reach $17.05 in the next year. This suggests a possible upside of 28.3% from the stock's current price. View Analyst Price Targets for Ironwood Pharmaceuticals.
What is the consensus analysts' recommendation for Ironwood Pharmaceuticals?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ironwood Pharmaceuticals in the last year. There are currently 1 sell rating, 7 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ironwood Pharmaceuticals.
Has Ironwood Pharmaceuticals been receiving favorable news coverage?
News stories about IRWD stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Ironwood Pharmaceuticals earned a coverage optimism score of 1.7 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the immediate future.
Who are some of Ironwood Pharmaceuticals' key competitors?
Some companies that are related to Ironwood Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), SAGE Therapeutics (SAGE), Beigene (BGNE), Loxo Oncology (LOXO), Marina Biotech (MRNA), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Catalent (CTLT), Amarin (AMRN), Nektar Therapeutics (NKTR), Alkermes (ALKS), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), Array Biopharma (ARRY) and GW Pharmaceuticals PLC- (GWPH).
What other stocks do shareholders of Ironwood Pharmaceuticals own?
Who are Ironwood Pharmaceuticals' key executives?
Ironwood Pharmaceuticals' management team includes the folowing people:
- Dr. Peter M. Hecht, Co-Founder, CEO & Director (Age 55)
- Ms. Gina R. Consylman CPA, CFO, Sr. VP & Treasurer (Age 46)
- Dr. Mark G. Currie, Sr. VP, Chief Scientific Officer and Pres of R&D (Age 64)
- Ms. Halley E. Gilbert, Sr. VP, Chief Legal Officer & Sec. (Age 49)
- Mr. Thomas A. McCourt, Pres (Age 62)
Who are Ironwood Pharmaceuticals' major shareholders?
Ironwood Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include MFN Partners Management LP (3.21%), Orbimed Advisors LLC (1.87%), Westfield Capital Management Co. LP (1.28%), Norges Bank (1.23%), Northern Trust Corp (1.11%) and Geode Capital Management LLC (1.08%). Company insiders that own Ironwood Pharmaceuticals stock include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Institutional Ownership Trends for Ironwood Pharmaceuticals.
Which institutional investors are selling Ironwood Pharmaceuticals stock?
IRWD stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, New York State Common Retirement Fund, PNC Financial Services Group Inc., First Trust Advisors LP, MetLife Investment Advisors LLC, California Public Employees Retirement System, Bank of New York Mellon Corp and Fisher Asset Management LLC. Company insiders that have sold Ironwood Pharmaceuticals company stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.
Which institutional investors are buying Ironwood Pharmaceuticals stock?
IRWD stock was purchased by a variety of institutional investors in the last quarter, including MFN Partners Management LP, Norges Bank, Millennium Management LLC, D. E. Shaw & Co. Inc., Canada Pension Plan Investment Board, Caption Management LLC, Ontario Teachers Pension Plan Board and Westfield Capital Management Co. LP. View Insider Buying and Selling for Ironwood Pharmaceuticals.
How do I buy shares of Ironwood Pharmaceuticals?
Shares of IRWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ironwood Pharmaceuticals' stock price today?
One share of IRWD stock can currently be purchased for approximately $13.29.
How big of a company is Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals has a market capitalization of $2.06 billion and generates $346.64 million in revenue each year. The biotechnology company earns $-282,370,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.
What is Ironwood Pharmaceuticals' official website?
How can I contact Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-621-7722 or via email at [email protected]
MarketBeat Community Rating for Ironwood Pharmaceuticals (NASDAQ IRWD)
MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe IRWD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRWD will underperform the S&P 500 over the long term. You may vote once every thirty days.
